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Objective: Constipation is common and a signiﬁcant problem in pregnant women. The purpose of this
study was to examine the efﬁcacy and the safety of daikenchuto in pregnant women with constipation.
Material and methods: This was a prospective study, and a total of 20 patients were registered between
February 2010 and August 2012. The patients received 7.5 g/d of daikenchuto for 28 days from the day of
registration. All enrolled patients were asked to complete the constipation assessment scale (CAS) every
day. In addition, we measured the aspartate transaminase, alanine transaminase, blood urea nitrogen,
and creatinine levels to assess the adverse effects of daikenchuto.
Results: The CAS scores were signiﬁcantly lower at 28 days after daikenchuto treatment (p ¼ 0.019), with
a signiﬁcant effect achieved on Day 1. The impact of the therapy was greatest in the second trimester
(p ¼ 0.043). No signiﬁcant adverse effects of daikenchuto were observed, and the rates of preterm birth
and pregnancy-induced hypertension were 10% and 5%, respectively, which are similar to previously
reported values.
Conclusion: We herein demonstrated the efﬁcacy and safety of daikenchuto in pregnant women with
constipation. We hope that our ﬁndings will aid in the management of constipation in pregnant women.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Constipation is a signiﬁcant problem in pregnant women and is
oftenmanagedwith a combination of stool softeners, laxatives, and
dietary modiﬁcations (e.g. increased ﬁber intake) [1]. Although the
frequency of stools is often improved with the above therapies,
uncomfortable abdominal symptoms, such as abdominal disten-
sion and pain, often persist [2].
Daikenchuto (TJ-100), a traditional Japanese herbal medicine, is
commonly used to treat adhesive bowel obstruction and chronic
constipation [2,3]. This compound is composedof extract granules of
Japanese pepper, processed ginger, ginseng radix, and maltose
powder derived from rice. Daikenchuto extract powder (Tsumura &
Co., Tokyo, Japan) is manufactured as an aqueous extract containing
2.2% Japanesepepper, 5.6%processedginger, 3.3%ginseng, and88.9%
maltose syrup powder. The main ingredients of daikenchuto arend Gynecology, Nagoya Uni-
ku, Nagoya 466-8550, Japan.
da).
bstetrics & Gynecology. Publishedhydroxy-alpha-sanshool (Japanese pepper), 6-shogaol (processed
ginger), and ginsenoside Rb1 (ginseng radix). Contamination studies
have certiﬁed daikenchuto to be free of unexpected pharmaceutical
ingredients, toxins, pesticides, microbes, and heavy metals.
Treatmentwith daikenchuto has been reported to be effective for
postoperative ileus [4], irritable bowel syndrome [5], and con-
stipation in both children and Parkinson's patients [6,7]. Recently,
evidence has accumulated regarding the following mechanisms of
action of daikenchuto: the activation of endogenous adrenome-
dullin in patients with Crohn's disease [8], anti-inﬂammatory ef-
fects [9], increased gastrointestinal motility [10], and the
upregulation of the blood ﬂow in the colon [11]. The clinical efﬁcacy
of daikenchuto is now well established; however, there are no re-
ports regarding its efﬁcacy or safety in pregnant women with
constipation.
The purpose of this study was to examine the efﬁcacy of dai-
kenchuto in pregnant women with constipation. In addition, we
performed maternal blood tests focused on the liver and renal
functions during treatment and assessed the outcomes of preg-
nancy in order to evaluate the safety of daikenchuto.by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
Table 1
Maternal characteristics and outcomes of pregnancy.
n ¼ 20
Maternal background
Maternal age (y) 35.0 (21e41)
Nulliparity 5 (25%)
Maternal body mass index 21.6 (17.9e26.7)
Pregnancy outcomes
GA at delivery, weeks 38.0 (33e41)
Neonatal birth weight (g) 2730 (1906e3762)
Fetal growth SD 0.1 (1.8 to1.4)
Male neonate 90 (45%)
Umbilical artery pH 7.33 (7.20e7.44)
Preterm birth 2 (10%)
Pregnancy-induced hypertension 1 (5%)
Low birth weight infant (< 2500 g) 3 (15%)
Data are presented as the mean (range) or n (%).
BMI ¼ body mass index; GA ¼ gestational age; SD ¼ standard deviation.
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Patients
This was a prospective interventional one-arm study conducted
with the aim of determining the efﬁcacy and safety of daikenchuto
in pregnant women between February 2010 and August 2012 at
Nagoya University Hospital, Nagoya, Japan. We excluded the pa-
tients with previous abdominal or pelvic surgery and ﬁnally
registered a total of 20 healthy pregnant women suffering with
constipation during this period. The patients received 7.5 g/day of
daikenchuto for 28 days from the day of registration. In addition, we
measured the aspartate transaminase (ALT), alanine transaminase
(AST), blood urea nitrogen (BUN), and creatinine levels before and
after treatment in order to assess the adverse effects of daikenchuto.
All patients provided their written informed consent to participate
in this study, which was approved by the Ethics Committee of
Nagoya University Hospital.
Maternal and neonatal data were extracted from the patients'
records, including maternal age, body mass index, gestational age
at delivery, neonatal birth weight and sex, and umbilical pH at
birth. Preterm delivery was deﬁned as delivery at < 37 weeks of
gestation. Pregnancy-induced hypertension was deﬁned as the
occurrence of gestational hypertension and proteinuria during
pregnancy, with the reversal of these conditions after delivery.
Gestational hypertension was deﬁned as a systolic blood pressure
of > 140 mmHg or diastolic blood pressure of > 90 mmHg after
20 weeks of gestation in previously normotensive patients. Pro-
teinuria was deﬁned as a protein level above 300 mg on 24-hour
urine collection.
Constipation assessment scale
The patients enrolled in this study were asked to complete the
constipation assessment scale (CAS) every day. The CAS was
introduced to determine whether an individual is experiencing
constipation and assess the severity of the problem [12]. The scale
consists of eight descriptors of constipation: (1) abdominal
distension or bloating; (2) a change in the amount of gas passed
rectally; (3) a reduced frequency of bowel movements; (4) liquid
stools; (5) rectal fullness or pressure; (6) rectal pain during bowel
movements; (7) small stools; (8) the inability to pass stool [12]. The
patients was asked to rate whether the item is no problem, some
problem, or a severe problem. No problem is scored as 0, some
problem as 1, and severe problem is scored as 2. The patient was then
asked to respond to each item, and the ratings are summed to
obtain a total score, which ranges from 0, representing no problems
with constipation, to 16, indicating severe constipation. Completing
this scale takes less than 2 minutes on average.
Statistics
The data were entered into a spreadsheet (Excel; Microsoft
Japan Co., Ltd., Tokyo, Japan), and SPSS was used for the data
analysis (V.19.0; SPSS Japan Inc., Tokyo, Japan). The Wilcoxon
signed-rank test was used to compare the CAS scores. In the box
and whisker plot, the data are presented as the mean ± quartile
deviation. A p-value of < 0.05 was considered to be signiﬁcant.
Results
Maternal characteristics
The background characteristics of the patients are shown in
Table 1. Aside from having constipation, all participants werehealthy pregnant women. A total of six patients were in the ﬁrst
trimester (<14 weeks of gestation), eight patients were in the
second trimester (14e27 weeks of gestation) and six patients were
in the third trimester (> 28 weeks of gestation) at the time of
registration. The rates of preterm birth and pregnancy-induced
hypertension were 10% and 5%, respectively, which are similar to
those reported [22] in pregnant Japanese women.
Effects of daikenchuto based on the CAS scores
We examined the CAS scores at before and after daikenchuto
therapy (Figure 1). The CAS scores were signiﬁcantly lower at
28 days after daikenchuto treatment (p ¼ 0.019), indicating that
daikenchuto signiﬁcantly improves constipation in pregnant
women. We then examined the CAS scores in each of the eight
categories and found that abdominal distension or bloating, a
reduced frequency of bowel movements and small stools each
signiﬁcantly improved after daikenchuto treatment (p ¼ 0.013,
0.022, and 0.046, respectively).
Effects of daikenchuto based on the CAS scores in each trimester
We examined the CAS scores before and after daikenchuto
therapy in each trimester (Figure 2). The CAS scores were signiﬁ-
cantly lower in the second trimester (p ¼ 0.043); however, no
signiﬁcant differences were observed in the ﬁrst and third tri-
mesters (p ¼ 0.357 and 0.273, respectively). Therefore, we
concluded that daikenchuto is useful for treating constipation in
pregnant women in the second trimester in particular.
Time course of the CAS scores
We examined the time course of the CAS scores, as shown in
Figure 3. On Day 1 after the initiation of daikenchuto treatment, the
CAS scores signiﬁcantly improved (p ¼ 0.002). Thereafter, the CAS
scores did not differ signiﬁcantly from those observed on Day 1.
These results indicate that the effects of daikenchuto are noticed by
patients the day after the start of treatment.
Evaluation of the safety of daikenchuto
We examined the AST, ALT, BUN, and creatinine levels before
and after treatment. The mean levels of these parameters were as
follows (before vs. after treatment): 16 IU/L versus 17 IU/L for ALT,
11 IU/L versus 12 IU/L for AST, 8.0 mg/dL versus 8.0 mg/dL for BUN,
and 0.45 mg/dL versus 0.46 mg/dL for creatinine. No signiﬁcant
Figure 1. Constipation assessment scale (CAS) scores at before and after daikenchuto
therapy. The CAS scores were signiﬁcantly lower after daikenchuto treatment
(p ¼ 0.019), indicating that daikenchuto signiﬁcantly improves constipation in pregnant
women. The mean CAS score before and after treatment was 10.0 and 5.0, respectively.
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exhibited abnormal values of the above parameters. During the
treatment period, the clinical courses of both the mothers and fe-
tuses were uneventful in all cases.
Discussion
This is the ﬁrst study of the efﬁcacy of daikenchuto in pregnant
women with constipation. Our results showed that daikenchuto
signiﬁcantly improves the symptoms of constipation, including
abdominal distension or bloating, a reduced frequency of bowel
movements and small stools among the eight categories included
in the CAS. Daikenchuto has been reported to decrease the volume
of bowel gas in both male and nonpregnant female patients [2,13],
similar to the effect observed among pregnant women in theFigure 2. Constipation assessment scale (CAS) scores before and after daikenchuto therapy in
scores were signiﬁcantly lower in the second trimester (p ¼ 0.043); however, no signiﬁ
respectively). The mean CAS scores before and after treatment were 10.0 and 8.0 in the ﬁrs
respectively.present study. Therefore, we recommend treatment with daiken-
chuto in pregnant women suffering from constipation, primarily
that complicated with abdominal distension. We also examined the
period from the initiation of daikenchuto therapy with respect to
improvements in constipation and found that the CAS scores
signiﬁcantly improved on Day 1 after the initiation of daikenchuto
treatment. These results indicate that the effects of daikenchuto are
noticeable to patients within one day after the start of treatment.
We believe that this information provides useful advice for
patients.
Furthermore, we examined the efﬁcacy of daikenchuto in each
trimester and observed a signiﬁcant in the second trimester only.
Although the CAS scores had a tendency to improve in the third
trimester, the difference was not signiﬁcant. We speculate that the
following reasons may account for this phenomenon. First, the
progesterone levels in pregnant women increase slowly during the
ﬁrst and second trimesters and rapidly during the third trimester.
The level of progesterone has been reported to be a possible etio-
logical factor for constipation [14e16]; therefore, the particular
hormonal environment in the third trimester may explain the
present results. Second, the uterus is largest in size in the third
trimester, and bowel movements appear to be impaired due to
compression of the uterus during this time. Lastly, the sample size
was small in the present study. Among the six third trimester pa-
tients registered in this study, ﬁve exhibited improved CAS scores,
while one showed disease exacerbation, with a decrease in the CAS
score of 4e9. This may explain the lack of power to demonstrate a
statistically signiﬁcant difference. Therefore, a larger study is war-
ranted to elucidate this issue. Similarly, no signiﬁcant effects were
noted in the ﬁrst trimester. In the ﬁrst trimester, some patients
suffer from hyperemesis and symptoms such as nausea, vomiting
and decreased food intake. In such circumstances, as well as under
conditions of a hypovolemic state, the effects of daikenchuto on
constipation may be limited.each trimester. (A) First trimester, (B) second trimester and (C) third trimester. The CAS
cant differences were observed in the ﬁrst or third trimester (p ¼ 0.357 and 0.273,
t trimester, 10.0 and 3.0 in the second trimester, and 7.0 and 5.0 in the third trimester,
Figure 3. Time course of the constipation assessment scale (CAS) scores. On Day 1
after the initiation of daikenchuto therapy, the CAS scores signiﬁcantly improved
(p ¼ 0.002). Thereafter, the CAS scores did not signiﬁcantly differ from those observed
on Day 1. The mean CAS score was 10.0 before treatment, 5.0 on Day 1, 5.0 on Day 2, 6.0
on Day 3, 5.0 on Day 7, 4.0 on Day 14, and 5.0 after treatment. * p < 0.05 compared with
Pre group.
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in this study. In Japan, daikenchuto is used in pregnant women in
Japan to treat constipation, and is covered by public insurance.
According to the animal reproductive toxicology studies, daiken-
chuto has failed to demonstrate a risk to the fetus. Therefore we
consider that daikenchuto can be regarded as safe for the ﬁrst
trimester of pregnancy. Moreover, daikenchuto has been reported to
have no effect on either spontaneous contractions or the contractile
response of the uterus [17] and is therefore considered to be safe for
pregnant patients. In the present study, among the total 20 pa-
tients, the incidence of preterm birth and pregnancy-induced hy-
pertension was 10% (2 patients) and 5% (1 patient), respectively.
The prevalence of preterm birth and pregnancy-induced hyper-
tension have been reported to be approximately 11% [18] and 7%
[19,20], respectively, which are similar to our ﬁndings in this study.
Furthermore, the clinical courses of both the mothers and fetuses
during daikenchuto treatment were uneventful in this study. There
were no signiﬁcant effects on the ALT, AST, BUN, or creatinine levels,
and no patients exhibited any abnormal values of these parameters.
Therefore, we can conclude that there are no signiﬁcant adverse
effects of daikenchuto in pregnant women, despite the small
number of cases in this analysis.
There are several limitations associated with this study. First,
the number of cases was small. A larger study is thus required to
overcome this limitation. Second, the CAS, which was employed in
the present study to evaluate the symptoms of constipation, con-
sists of a questionnaire, and the results are therefore subjective.
However, the diagnosis of constipation is frequently made by the
patient, and a symptom-based diagnosis of constipation is accept-
able for most clinicians. Hence, the CAS method exhibits sufﬁcient
evidence of validity and reliability [12] and is potentially useful as a
quick assessment tool for evaluating constipation. Third, we have
no data regarding food intake and dietary patterns of the patients in
this study. Intake of rice and pulses was negatively and that of
confectioneries and bread positively associated with functional
constipation among a population of young Japanese women [21].
Therefore the further study is required about this issue. Finally, only
25% of cases were nulliparous in this study. To the best of our
knowledge, nothing has been reported on whether the parity has
an inﬂuence on the disease rate of constipation. Further study is
necessary about this issue.
In conclusion, this study is the ﬁrst to assess the efﬁcacy and
safety of daikenchuto in pregnant women with constipation. Our
ﬁndings demonstrated that the efﬁcacy of daikenchuto therapy isgreatest in the second trimester and that a signiﬁcant effect is
achieved the ﬁrst day after the start of treatment. Although the
present data may have some limitations, we hope that our ﬁndings
will aid in the management of constipation in pregnant women.Conﬂicts of interest
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